Αποτελέσματα Αναζήτησης
10 Νοε 2020 · The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. New evidence and future directions of antithrombotic treatment in East Asian patients are proposed and the unique risk–benefit trade-off in East Asians is proposed.
Young-Hoon Jeong. CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, South Korea. Division of Cardiology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea.
Huo, Yong ; Jeong, Young Hoon ; Gong, Yanjun et al. / 2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. In: Science Bulletin. 2019 ; Vol. 64, No. 3. pp. 166-179.
Platelet inhibition with the prasugrel active metabolite is 30-47% higher in East Asian patients. Inhibition of platelet inhibition is comparable with 10 mg daily in white patients and 5 mg daily in East Asian patients.
Young-Hoon JEONG, Director Thrombosis and Biomarker Center | Cited by 6,148 | of Chung-Ang University, Seoul | Read 334 publications | Contact Young-Hoon JEONG
Young-Hoon Jeong, MD, PhD. On behalf of the ACCEL-LOADING-ACS Investigators. Gyeongsang National University Hospital, Jinju, Korea; Sinai Center for Thrombosis Research, Baltimore, MD, USA. ClinicalTrials.gov Identifier: NCT01354808. Presenter Disclosure Information.
Young-Hoon Jeong, MD, PhD, FAHA. Director, CAU Thrombosis & Biomarker Center, Chung-Ang University Gwangmyeong Hospital. Verified email at cauhs.or.kr - Homepage. thrombogenicity platelet...
